Lexicon earns third $10M milestone from Novo Nordisk
Lexicon Pharmaceuticals says it earned a third $10 million milestone payment from Novo Nordisk after a key phase 1 development milestone for LX9851.
LXRX NVO Lexicon Pharmaceuticals earns third $10M milestone payment from Novo nordisk following achievement of key phase 1 development milestone for lx9851 Lexicon Pharmaceuticals, - eligible for up to $1B in upfront and milestone payments plus royalties - Has earned $75M of $1B potential milestone payments from Novo nordisk